Developer of therapeutics designed to treat fibrotic diseases. The company develops a drug discovery platform to regulate the monocyte-derived cell populations that play roles in fibrotic, inflammatory and autoimmune diseases, enabling patients with medicines to cure their diseases.
Promedior does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.
The stock price for Promedior will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).
